KMT2A and leukemia: While interactions with the components of B‐cell receptor signaling or TGF‐beta receptor signaling pathways were not surprising, given the prevalence of MLL1 fusions in leukemia (Buchner and Muschen, 2014; Rouce et al., 2016), the observation of extensive interactions with components of the EGFR and androgen signaling pathways was intriguing, as these pathways are primarily dysregulated in solid tumors.